What is the half-life of amoxicillin (Augmentin) in the 875/125 mg dose?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 23, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Half-Life of Amoxicillin in Augmentin 875/125 mg

The half-life of amoxicillin in the 875/125 mg formulation of Augmentin is approximately 61 minutes (approximately 1 hour), while clavulanic acid has a slightly shorter half-life of approximately 1.03 hours. 1

Pharmacokinetic Profile

  • Amoxicillin demonstrates a terminal half-life of 61.3 minutes following oral administration, which is consistent across different formulations including the 875/125 mg dose 1

  • Clavulanic acid has a terminal half-life ranging from 1.03 to 1.27 hours, which is similar to amoxicillin but slightly variable depending on the specific study 2, 3

  • Peak serum concentrations of amoxicillin occur at approximately 1-2 hours after administration, with the 875 mg dose producing a mean Cmax of 13.8 ± 4.1 mcg/mL and an AUC of 35.4 ± 8.1 mcg•hr/mL 1

  • Peak serum levels for clavulanic acid occur slightly earlier at approximately 1 hour, reaching concentrations of 2.55 ± 0.54 mcg/mL after the 875/125 mg dose 4

Clinical Implications of the Short Half-Life

  • The short half-life of both components necessitates twice-daily dosing for the 875/125 mg formulation to maintain adequate therapeutic concentrations 5, 6

  • Approximately 60% of amoxicillin is excreted unchanged in the urine within 6-8 hours, and detectable serum levels persist up to 8 hours after oral administration 1

  • Beta-lactam antibiotics like amoxicillin demonstrate time-dependent killing with only a brief post-antibiotic effect, meaning they require frequent dosing to maintain concentrations above the minimum inhibitory concentration (MIC) for optimal bacterial eradication 7

  • By 12 hours after dosing, plasma amoxicillin concentrations drop to very low levels (approximately 0.05 mcg/mL), which supports the twice-daily dosing regimen without significant dose-to-dose accumulation 2

Dosing Considerations Based on Half-Life

  • The 875/125 mg formulation is specifically designed for twice-daily administration to compensate for the short half-life while providing adequate coverage for respiratory infections, skin and soft tissue infections, and other moderate-to-severe bacterial infections 5, 6

  • For optimal pharmacodynamic effect, the time above MIC (T>MIC) should exceed 40-50% of the dosing interval, which the 875/125 mg twice-daily regimen achieves for most susceptible organisms 8, 2

  • Pharmacokinetically enhanced formulations (such as 2000/125 mg extended-release) were developed to extend the T>MIC to approximately 49-79% of the dosing interval, addressing the limitation of the short half-life for organisms with higher MICs 8, 2

Special Populations

  • In patients with end-stage renal disease on hemodialysis, the half-life of amoxicillin extends dramatically to 13.6 hours on non-dialysis days, requiring significant dose adjustment 3

  • During hemodialysis, the half-life decreases to 2.30 hours for amoxicillin and 1.19 hours for clavulanic acid, with approximately 64-65% of both drugs removed during a 4-hour dialysis session 3

References

Guideline

Amoxiclav Dosing Guidelines for Adults

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Amoxicillin-Clavulanate Dosing for Bacterial Infections

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Pharmacodynamics of amoxicillin/clavulanic acid against Haemophilus influenzae in an in vitro kinetic model: a comparison of different dosage regimens including a pharmacokinetically enhanced formulation.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2002

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.